全文获取类型
收费全文 | 1682篇 |
免费 | 101篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 51篇 |
妇产科学 | 9篇 |
基础医学 | 225篇 |
口腔科学 | 29篇 |
临床医学 | 127篇 |
内科学 | 437篇 |
皮肤病学 | 27篇 |
神经病学 | 95篇 |
特种医学 | 31篇 |
外科学 | 341篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 93篇 |
眼科学 | 22篇 |
药学 | 113篇 |
中国医学 | 5篇 |
肿瘤学 | 140篇 |
出版年
2024年 | 2篇 |
2023年 | 6篇 |
2022年 | 16篇 |
2021年 | 44篇 |
2020年 | 36篇 |
2019年 | 40篇 |
2018年 | 45篇 |
2017年 | 57篇 |
2016年 | 56篇 |
2015年 | 57篇 |
2014年 | 83篇 |
2013年 | 95篇 |
2012年 | 130篇 |
2011年 | 127篇 |
2010年 | 89篇 |
2009年 | 69篇 |
2008年 | 94篇 |
2007年 | 103篇 |
2006年 | 87篇 |
2005年 | 78篇 |
2004年 | 89篇 |
2003年 | 76篇 |
2002年 | 74篇 |
2001年 | 18篇 |
2000年 | 16篇 |
1999年 | 15篇 |
1998年 | 11篇 |
1997年 | 14篇 |
1996年 | 10篇 |
1995年 | 8篇 |
1994年 | 3篇 |
1993年 | 9篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 7篇 |
1987年 | 6篇 |
1986年 | 5篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 8篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 7篇 |
1979年 | 7篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1940年 | 2篇 |
1938年 | 2篇 |
排序方式: 共有1784条查询结果,搜索用时 265 毫秒
11.
Jo-Lynn S. Tan Niranjan Sathianathen Marcus Cumberbatch Prokar Dasgupta Alexandre Mottrie Ronney Abaza Koon Ho Rha Thyavihally B. Yuvaraja Dipen J. Parekh Umberto Capitanio Rajesh Ahlawat Sudhir Rawal Nicolò M. Buffi Ananthakrishnan Sivaraman Kris K. Maes Gagan Gautam Francesco Porpiglia Levent Turkeri Mahendra Bhandari Benjamin Challacombe James Roscoe Porter Craig R. Rogers Daniel A. Moon 《BJU international》2021,128(Z3):30-35
12.
Rabea Asleh Hilmi Alnsasra Amir Lerman Alexandros Briasoulis Naveen L. Pereira Brooks S. Edwards Takumi Toya John M. Stulak Alfredo L. Clavell Richard C. Daly Sudhir S. Kushwaha 《American journal of transplantation》2021,21(2):626-635
We have previously described the use of sirolimus (SRL) as primary immunosuppression following heart transplantation (HT). The advantages of this approach include attenuation of cardiac allograft vasculopathy (CAV), improvement in glomerular filtration rate (GFR), and reduced malignancy. However, in some patients SRL may cause significant proteinuria. We sought to investigate the prognostic value of proteinuria after conversion to SRL. CAV progression and adverse clinical events were studied. CAV progression was assessed by measuring the Δ change in plaque volume (PV) and plaque index (PI) per year using coronary intravascular ultrasound. Proteinuria was defined as Δ urine protein ≥300 mg/24 h at 1 year after conversion to SRL. Overall, 137 patients were analyzed (26% with proteinuria). Patients with proteinuria had significantly lower GFR (P = .005) but similar GFR during follow-up. Delta PV (P < .001) and Δ PI (P = .001) were significantly higher among patients with proteinuria after adjustment for baseline characteristics. Multivariate Cox regression analysis showed higher all-cause mortality (hazard ratio 3.8; P = .01) with proteinuria but similar risk of CAV-related events (P = .61). Our results indicate that proteinuria is a marker of baseline renal dysfunction, and that HT recipients who develop proteinuria after conversion to SRL have less attenuation of CAV progression and higher mortality risk. 相似文献
13.
Abhinit Kumar Sudhir Bahadur Suberendra Kumar Sima Mukhopadhyay Meera Mathur 《Indian journal of otolaryngology and head and neck surgery》2000,52(3):230-234
Twelve patients undergoing surgery between May 1995 and March 1999 for malignant tumours of the paranasal sinuses abutting
or invading the orbital walls were studied for the need to remove orbital contents. Alt patients were evaluated clinically,
radiologically (CT Scan) and per-operatively to delineate the extent of orbital invasion. Combined regimen (Surgery + Radiotherapy)
were used in all patients. A biopsy from periorbita was taken when eye was spared. It was found that per-operative evaluation
of the orbit is equally specific in comparision to clinical and CT Scan combined and eye may be preserved in selected patients
with involvement of orbital periosteum provided there is no frank soft tissue mass in the orbit. 相似文献
14.
Sanjeev Gupta Sudhir Bahadur M. Mathur Aloke Thakar 《Indian journal of otolaryngology and head and neck surgery》2000,52(3):253-256
Radical neck dissection is a standard procedure carried out for the teatment of palpable nodes in the neck but if carried
out electively in cases where there are no palpable nodes in the neck it is considered to be an overtreatment with its associated
morbity. Lateral neck dissection was carried out on twenty patients who had T31 T4 lesion of the larynx and hypophar-vnx with
NO neck. The dissection entails removal of Level II. III and IV nodes. Occult metastasis 80% and 85% respectively. The mean
follow up was 13 monts. It appears from our study that elective lateral neck dissection is a promising and safe procedure
and may be useful as an important prognostic tool in sampling the lymph nodes and predicting recurrences in the neck. 相似文献
15.
Sangeeta Varty Dinesh Vaidya Kamal Parasram Divya Prabhat Sudhir Joshi 《Indian journal of otolaryngology and head and neck surgery》2000,52(2):143-146
Tuberculosis of the middle ear it a rare disease. Due to change in the typical clinical pattern and decrease in incidence,
there is a delayed or missed diagnosis and can lead to increased morbidity. We pretent 5 cases of Tuberculous Otitis Media
treated over a period of 2 years, highlighting the fact that it must be considered as a differential diagnosis of persistent
suppurative otitis media. 相似文献
16.
Roberto Bianco Roberta Caputo Rosa Caputo Vincenzo Damiano Sabino De Placido Corrado Ficorella Sudhir Agrawal A Raffaele Bianco Fortunato Ciardiello Giampaolo Tortora 《Clinical cancer research》2004,10(14):4858-4864
PURPOSE: The epidermal growth factor receptor (EGFR) may play a relevant role in the progression, hormone therapy resistance, and prognosis of prostate cancer patients. Also MDM2, a negative p53 regulator that interacts with retinoblastoma (Rb), E2F, p19(arf) and the ras-mitogen-activated protein kinase(MAPK) cascade plays an important role in prostate cancer progression and prognosis. On the basis of the EGFR and MDM2 role in integrating signaling pathways critical for prostate cancer progression, we investigated whether their selective combined blockade may have a cooperative antitumor effect in prostate cancer. For this purpose, we have used the EGFR tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) and a second generation hybrid oligonucleotide antisense MDM2 (AS-MDM2), respectively. EXPERIMENTAL DESIGN: Gefitinib and AS-MDM2 were administered to hormone-refractory and hormone-dependent human prostate cancer cells in vitro and to mice bearing tumor xenografts, evaluating the effects on growth, apoptosis, and protein expression, in vitro and in vivo. RESULTS: We demonstrated that the combination of gefitinib and AS-MDM2 synergistically inhibits the growth of hormone-independent prostate cancer cells in vitro. This effect is accompanied by the inhibition of MDM2, phosphorylated Akt (pAkt), phosphorylated MAPK (pMAPK), and vascular endothelial growth factor (VEGF) expression and by Rb hypophosphorylation. The combination of the two agents in nude mice bearing the same hormone-independent tumors caused a potent cooperative antitumor effect. Tumor samples analysis confirmed the inhibition of MDM2, pAkt, pMAPK, VEGF, and basic fibroblast growth factor expression. CONCLUSIONS: This study shows that EGFR and MDM2 play a critical role in the growth of prostate cancer, especially hormone-dependent, and that their combined blockade by gefitinib and AS-MDM2 causes a cooperative antitumor effect, supporting the clinical development of this therapeutic strategy. 相似文献
17.
Sudhir Tauro Charles Craddock Karl Peggs Gulnaz Begum Premini Mahendra Gordon Cook Judith Marsh Donald Milligan Anthony Goldstone Ann Hunter Asim Khwaja Raj Chopra Timothy Littlewood Andrew Peniket Anne Parker Graham Jackson Geoff Hale Mark Cook Nigel Russell Stephen Mackinnon 《Journal of clinical oncology》2005,23(36):9387-9393
PURPOSE: The toxicity of allogeneic stem-cell transplantation can be substantially reduced using a reduced-intensity conditioning (RIC) regimen. This has increased the proportion of patients with myeloid malignancies eligible for allogeneic transplantation. However, the capacity of RIC allografts to produce durable remissions in patients with acute myeloid leukemia (AML) and myelodysplasia (MDS) has not yet been defined, and consequently, the role of RIC allografts in the management of these diseases remains conjectural. PATIENTS AND METHODS: Seventy-six patients with high-risk AML or MDS received an allograft using a fludarabine/melphalan RIC regimen incorporating alemtuzumab. The median age of the cohort was 52 years (range, 18 to 71 years). RESULTS: The 100-day transplantation-related mortality rate was 9%, and no patient developed greater than grade 2 graft-versus-host disease. With a median follow-up of 36 months (range, 13 to 70 months), 27 patients were alive and in remission, with 3-year actuarial overall survival (OS) and disease-free survival (DFS) rates of 41% and 37%, respectively. The 3-year OS and DFS rates of patients with AML in complete remission at the time of transplantation were 48% and 42%, respectively. Disease relapse was the most common cause of treatment failure and occurred at a median time of 6 months after transplantation. All but one patient destined to relapse did so within 24 months of transplantation. CONCLUSION: The extended follow-up in this series identifies a high risk of early disease relapse but provides evidence that RIC allografts can produce sustained DFS in a significant number of patients with AML who would be ineligible for allogeneic transplantation with myeloablative conditioning. 相似文献
18.
19.
20.